The regulation of PTEN intrinsic biochemical properties has not been fully elucidated. In this report, we investigated the role of PTEN carboxyl-terminal tail domain in regulating its membrane-targeting and catalytic functions. Characterization of a panel of PTEN phosphorylation site mutants revealed that mutating Ser385 to alanine (S385A) promoted membrane localization in vivo, and phosphatase activity in vitro. Furthermore, S385A mutation was associated with a substantial reduction in t h e p h o s p h o r y l a t i o n o f t h e Ser380/Thr382/Thr383 cluster. Therefore, S e r 3 8 5 c o u l d p r i m e a d d i t i o n a l dephosphorylation events to regulate PTEN catalytic activity. Moreover, substituting Ser380/Thr382/Thr383 to phospho-mimic residues reversed the phosphatase activity of the S385A mutation. Next, we further defined the underlying mechanisms responsible for the C-terminal tail region in modulating PTEN biological activity. We have identified an interaction between the 71-amino acid carboxylterminal tail region and the CBRIII motif of the C2 domain, which has been implicated in membrane binding. In addition, a synthetic phospho-mimic peptide encompassing the phosphorylation site cluster between amino acid 368-390 within the tail region mediated the suppression of PTEN catalytic activity in vitro. This same peptide when expressed in cultured cells also impeded PTEN membrane localization and enhanced p-Akt levels. Thus, our data suggest that the C-terminal tail can act as an autoinhibitory domain to control both PTEN membrane recruitment and phosphatase activity.
INTRODUCTION
PTEN is a bona fide tumor suppressor gene frequently inactivated in multiple human tumors (1) (2) (3) (4) (5) (6) (7) (8) . PTEN encodes a phosphatidylinositol (3, 4, 5) triphosphate (PIP 3 ) phosphatase (PTPase) that plays a critical role in regulating the intracellular levels of PIP3 (9) (10) (11) . The mechanism by which PTEN targets to the plasma membrane is under intense investigation. In addition, how the intrinsic catalytic activity of PTEN is regulated has not been fully delineated.
The resolution of the PTEN crystal structure has provided biophysical data in identifying functional motifs responsible for mediating PTEN membrane binding (12) . PTEN possesses in its carboxyl (C)-terminus between amino acid (aa)186-351 a C2 domain, which is similar to that found in phospholipase A2 (cPLA2). In particular, the conserved CBRIII loop possesses nine positively charged and two hydrophobic residues that are implicated in phospholipids binding (12) (13) (14) . Consequentially, these interactions orientate the catalytic pocket towards the lipid bilayer. Furthermore, additional positively charged residues interfacing the lipid bilayer at Arg161, Lys163, and Lys164 have been shown to contribute to membrane binding through electrostatic interactions (14) .
Based on protease sensitivity assays, the 7-aa N-terminal and 49-aa C-terminal regions of PTEN are unstructured and therefore unable to be crystallized (12) . Nevertheless, structure-functional analysis of these regions has implicated their involvements in membrane binding and PTEN biological activities. The N-terminal 16-aa polybasic region constitutes a PIP 2 -binding motif that is essential for PTEN tumor suppressor function. Deletion of this region or the acquisition of a tumor-associated Lys→ Glu13 mutation greatly reduces PTEN membrane binding and tumor suppressing activity (15) (16) (17) (18) . PIP 2 binding to this motif greatly stimulates the intrinsic catalytic activity of PTEN (16, 18) . The fact that PIP 2 fails to stimulate PTEN when a soluble lipid substrate, Ins(1,3,4,5)P 3 , was used argue for a role of a PIP 2 -rich membrane in orientating the catalytic pocket of PTEN towards the lipid bilayer (18) . However, it has also been suggested that PIP 2 may activate PTEN through an allosteric mechanism (16) . All these findings favor an interfacial activation mechanism of PTEN at the lipid bilayer involving interactions of multiple membrane binding moieties (19) .
The C-terminal 63-aa region (aa347-399) of PTEN was initially referred to as the PEST domain (20) (21) (22) . There are six phosphorylation sites at Thr366, Ser370, Ser380, Thr382, Thr383, and Ser385 that are implicated in modulating PTEN tumor suppressor functions, subcellular distribution and stability. In general, PTEN mutants with these sites substituted with nonphosphorable amino acids have greater tumor suppressor activity, enhanced membrane affinity, and reduced protein stability (14, 20, 21, (23) (24) (25) (26) (27) (28) (29) . The biochemical basis for these observations is believed to be the result of a more open conformation displayed by these mutants (17, 20) . However, whether these phosphorylation sites contribute to the intrinsic catalytic activity of PTEN remained to be determined.
By mass spectroscopy, two Casein Kinase II (CKII) sites at Ser370 and Ser385 have been shown to be preferentially phosphorylated in vivo (30) . The biological relevance of phosphorylation at Ser370 and Ser385 is not well defined although a double mutant of S370A/S385A has been shown to have shorter half-life than the wild-type protein (24) . Additional phosphorylation sites at Ser362 and Thr366 have been reported to be the targets of Glycogen Synthase Kinase 3 (GSK3). It is speculated that phosphorylation at these sites constitutes a negative feedback mechanism in attenuating signaling events initiated by insulinlike growth factor (29) . Furthermore, ROCK has been shown to phosphorylate Ser229, Thr232, Thr319 and Thr321 within the C2 domain of PTEN in cells exposed to chemoattractants (31) .
The phosphorylation cluster composed of Ser380, Thr382 and Thr383 are believed to be minor sites (29, 30) . However, leptin has recently been reported to stimulate their phosphorylation and resulting in the inhibition of PTEN catalytic activity (32) . Furthermore, Thr383 has been identified as a putative autodephosphorylation site for PTEN, as its dephosphorylation greatly enhances the ability of PTEN to suppress cell migration in human glioblastoma cell lines (33) .
There is still considerable uncertainty in how the C-terminal domain of PTEN regulates its biochemical function. In this report, we provide evidence that this tail region mediates intramolecular interactions with the C2 domain. In addition, the PEST domain rich in acidic residues can serve as an autoinhibitory motif in suppressing PTEN catalytic activity.
EXPERIMENTAL PROCEDURES
Cell cultures-The PTEN-null human prostate carcinoma cell line PC3, and human kidney epithelial cell line 293T, were maintained in DMEM supplemented with 10% FBS. For transfection of 293T cells, 10 6 cells were transfected in 100-mm plates with 10 µg of DNA using 12 µl of Lipofectamine2000 (Invitrogen) in 6 ml of serum-and antibiotic-free DMEM for 4 h. Cells were lysed after 48 h of incubation. For gene transfer in PC3 cells, 10 5 cells on a 6-well plate were transfected with 2-4 µg of DNA using 2 µl of Lipofectamine2000 (Invitrogen) in 1 ml of serumand antibiotic-free DMEM for 4 h. Cells were analyzed after 48 h incubation.
Plasmids-The construction of the PTEN-WT cDNA has been described previously (22, 23) . For  the generation of PTEN S370A, S380A, T382A,  T383A, S385A, S370A/S385A, S380A/T382A/  T383A, S380E, S385E, S380D/T382E/T383E S385A and CBR3 mutants, standard PCR-based site-directed mutagenesis was used. All PTEN mutant cDNAs were restriction-digested with BamHI and EcoRI enzymes and cloned into the BglII and EcoRI sites of the expression vector, p C E F L -K Z -A U 5 . The MYR-PTEN was c o n s t r u c t e d b y f u s i n g a n a d a p t o r agcttctcgaggccgccaccatggggagtagcaagagcaagccta aggaccccagccagcgcg containing the myristoylation signal peptide (GSSKSKPKDPSQR) in the HindIII and BamHI sites of the pCEFL-KZ-AU5-PTEN expression plasmid. The ∆N16-PTEN mutant was generated by a tandem PCR-based strategy using two overlapping primers to delete the N-terminal 16-aa of PTEN: aaaagcttctcgaggccgccaccatgggatcc accgacttctacctaaagagatcc, and ttctacctaaagagatccat gcaagaggatggattcgactta. The PCR fragment was cloned into the HindIII and BglII sites of pCEFL-KZ-AU5-PTEN. GFP-Cp23 and GFP-Cp23/385E expression plasmids were generated by subcloning cDNA fragments encompassing aa368-390 of PTEN into the BglII-EcoRI sites of the pEGFP expression vector (Clontech).
Antibodies-The anti-PTEN mouse monoclonal antibody (Santa Cruz and Cascade), the antipSer380/pThr382/pThr383-PTEN polyclonal antibody (Cell Signaling), the anti-pS385-PTEN polyclonal antibody (AnaSpec), the anti-AU5 monoclonal antibody (Covance), the anti-Flag monoclonal antibody (Sigma), the polyclonal α-AKT, the polyclonal α-p-T308-AKT antibodies (Cell Signaling), the SP1 (Santa Cruz) and the LDH (Sigma) , were purchased from commercial sources. The anti-PTEN rabbit polyclonal antibody, GPC07, was raised against a fusion protein of GST and the C-terminal 216-aa of PTEN. The anti-p-S380-PTEN antibody was generated using a phospho-peptide: EPDHYRYpSDTTDSD as the immunogen (Research Genetics).
Immunoprecipitation-Cells were solubilized in buffer A: 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Nonidet P-40 (NP-40), 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM aprotinin, 2 mM leupeptin, 1 mM sodium orthovanadate (Na 3 VO 4 ), 1 mM sodium pyrophosphate (Na 4 P 2 O 7 ), and 10 mM sodium fluoride (NaF). 1 mg of total protein was immunoprecipitated with 1 µ g of α -Flag monoclonal antibody (Sigma) or α -PTEN polyclonal antibody for 5 h at 4 o C. Immunocomplexes were absorbed onto 30 µl of GammaBind G sepharose beads (Amersham) for 1 h at 4 °C. The immunoprecipitates were washed three times with 1 ml of lysis buffer, boiled in 30 µl of 2 x Laemmli buffer and subjected to Western blotting analysis.
Hypotonic subcellular fractionation-Cells were scraped in a hypotonic buffer composed of 20 mM HEPES pH 7.4, 5 mM Na 4 P 2 O 7 , 5 mM EGTA, 1 mM MgCl 2 , 1 mM Na 3 VO 4 , 1 mM PMSF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin. Cell extracts were homogenized with 30 strokes in a glass Douncer. Nuclei were pelleted at 500 x g for 5 min at 4 °C. The supernatant was centrifuged at 100,000 x g for 50 min at 4 °C. The supernatant was the cytosolic fraction. The pellet was resuspended in a Triton X-100 buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , and 10 mM NaF) and centrifuged at 18,000 x g for 10 min at 4°C. The supernatant was the membrane fraction.
Sucrose gradient-Cells were scraped in an extraction buffer (25 mM MES pH 6.5, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , and 10 mM NaF) for 20 min on ice. The extracts were homogenized by 30 strokes in a Dounce homogenizer, and sucrose was adjusted to 40%. The samples were placed on the bottom of an ultracentrifuge tube, and step sucrose gradient (5, 10, 15, 20, 25 , 30% in 25 mM MES, pH 6.5, 150 mM NaCl) was layered on top. The samples were centrifuged for 18 hours at 34,000 x g at 4 °C. 1 ml fraction was collected, diluted 1:1 with 25 mM MES, pH 6.5, 150 mM NaCl, and centrifuged again at 14,000 x g for 30 min. The pellets for each fraction were resuspended in 1 x Laemmli buffer, boiled and analyzed by Western blotting.
Saponin subcellular fractionation-Cells were lysed in 10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.01% Saponin, 5 mM EDTA, 2 mM EGTA, 1 mM PMSF, 10 µ g/ml aprotinin, 10 µ g / m l leupeptin, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , and 10 mM NaF for 20 min on ice. The lysates were centrifuged for 30 min at 18,000 x g . The supernatant was collected as the cytosolic fraction. The pellet was resuspended in 50 mM HEPES, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 10% glycerol, 1 mM PMSF, 10 µg/ml aprotinin, 10 µg/ml leupeptin, 1 mM Na 3 VO 4 , 1 mM Na 4 P 2 O 7 , 10 mM NaF, and centrifuged for 30 min at 18,000 x g . The supernatant was collected as the membrane fraction.
Nuclear-cytosol fractionation-Nuclear and cytoplasmic fractions was prepared using the NE-PER fractionation kit (Pierce) according to a modified manufacturer's protocol.
Immunofluorescence analysis-Cells were plated on poly-lysine-coated glass coverslips. Following fixation with 3% paraformaldehyde, cells were permeabilized with 0.2% Triton X-100 in PBS and blocked in 3% BSA/PBS. Samples were incubated overnight at 4 o C with anti-AU5 (1:500). Bound antibody was detected with an Alexa Fluor 488 anti-mouse secondary antibody (1:1000, Invitrogen). Nuclei were visualized with DAPI (1 µg/ml). Specimens were mounted onto glass slides and analyzed by confocal microscopy on a Leica TCS-SP inverted microscope with a 63x objective.
Purification of recombinant PTEN and C-Tail from bacteria-BL21 bacteria harboring pET15B-His-PTEN or pET15B-His-C-Tail were grown to A 600 = 0.5-0.7 and induced with 0.3 mM IPTG overnight at 25 °C, pelleted and resuspended in PBS with 2 mM β-mercaptoethanol, 1 mM PMSF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin. Cells were lysed by sonication, and Triton X-100 and NaCl were adjusted to 1% and 350 mM, respectively. Lysates were clarified by centrifugation at 18,000 x g and supernatant was treated with 20 µg/µl DNase I for 1 h at 4 °C. PTEN was purified on a HisTrap HP column (Amersham) using a 20-500 mM imidazole gradient. The monomeric protein was isolated through gel filtration on a Superdex 200 column (Amersham).
Purification of recombinant PTEN from insect cells-Sf9 cells were infected with baculoviruses
harboring His-tagged PTEN WT, S370A, T382A, T382A, T383A, S385A, S370A/S385A and T382A/T383A/S385A expression plasmids for 5-7 days. Cells were lysed in buffer A and monomeric PTEN was purified as described above. PTEN purified by this method has an average PIP 3 phosphatase activity of ~1.3 pmol/ng/min.
Phosphatase activity assay-Recombinant PTEN was incubated with 50 µ M synthetic diC 8 -PI(3,4,5)P 3 (Echelon) with or without 50 µM synthetic diC 8 -PI(4,5)P 2 (Echelon), both in soluble form for 10 min at 37 °C in a final volume of 25 µl. The reaction buffer was in 10 mM DTT and 25 mM Tris-HCl pH 8.0. The reaction was stopped with 100 µl of malachite green reagent (Echelon). The amount of phosphate released was measured by reading the absorbance at 620 nm. The amount of protein used was pre-determined and within the linear range of the reaction. The amount of phosphate released was normalized to the amount of protein used in the reaction. For measuring PTEN activity in vitro, 5x10 6 293T cells were transfected with 15 µg of expression plasmids using 9 µl of lipofectamine 2000 (Invitrogen). After 48 hours, cells were solubilized in 600 µl of a lysis buffer containing 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 2 mM DTT, 1 mM EDTA, 1 mM PMSF, 2 mM aprotinin, and 2 mM leupeptin. Approximately 3 mg of total cell extracts were immunoprecipitated with 5 µg of an anti-AU5 antibody for 4 h and immunocomplexes were affinity absorbed onto 30 µl of GammaBind G sepharose beads. PTEN phosphatase activity was then assayed as described above.
Peptide inhibition assay-20 nM of bacterial PTEN was incubated with 50 µ M synthetic diC 8 
RESULTS

Subcellular Distribution of PTEN in Cultured
Cells-To gain insights into the distribution of PTEN in different cellular compartments, the subcellular distribution of endogenous PTEN was investigated in three non-transformed cell lines, NIH3T3, MCF10A, and MDCK. Solubilizing cells with a hypotonic buffer followed by Triton X-100 (1%) extraction resulted in the majority of PTEN proteins being found in the cytosolic fractions. The levels of PTEN in the membrane fractions were almost undetectable under these experimental conditions (Fig. 1A ) . As has been reported previously, the use of a weaker non-ionic detergent, saponin (0.01%), increased the amount of PTEN in the membrane fraction to a detectable level in NIH3T3 cells (Fig. 1B) (34) . The potential of cross-contamination was monitored by using Lactate Dehydrogenase (LDH) and R-Ras as the cytoplasmic and membrane markers, respectively ( Fig. 1A and B) . In addition, the levels of PTEN in the nuclei of these cell lines were substantially lower than in the cytosolic fractions (Fig. 1C) . Furthermore, by sucrose gradient fractionation, PTEN was not detected in the caveolin-rich lipid raft fractions (Fig. 1D ). All these data were consistent with several previous reports showing the predominant cytosolic localization of PTEN in mammalian cells (34) .
Involvement of Ser380 and Ser385 in PTEN
Membrane targeting Capacity-Phosphorylation events in the C-tail region has been implicated in PTEN membrane binding capacity (14, 17) . However, the relative contribution of individual phosphorylation sites to membrane targeting in mammalian cells has not been clearly defined. For this, a panel of PTEN phosphorylation site mutants was constructed. They were consisted of single site mutants, S370A, S380A, T382A, T383A, S385A; a double site mutant, S370A/S385A; and a triple site mutant, S380A/T382A/T383A. Using a PTEN null cell line, PC3, PTEN mutants were transiently transfected and subjected to subcellular fractionation using the saponin-containing lysis buffer as described in Fig. 1B . Among the single site mutants, both S380A and S385A displayed 4-and 3.5-fold greater proportion in the membrane fraction when compared to wild-type PTEN, respectively ( Fig. 2A) . The double site mutant, S370A/S385A, has the highest membrane targeting capacity that was 5.5-fold greater than the wildtype protein. On the contrary, single site mutants, S370A and T382A, did not display differences from the wild-type protein. Finally, the T383A and the triple mutant only showed a 2-fold increase.
To ascertain the role of phosphorylation at positions Ser380 and Ser385 in membrane recruitment, we constructed two phospho-mimic mutants, S380E and S385E. Using the saponinbased fractionation procedures, the S380E mutant showed similar membrane distribution when compared to the S380A mutant. On the contrary, the S385E mutant has a significantly lower membrane binding capacity than the S385A mutant (Fig. 2B) .
To further substantiate these results, we constructed a membrane-targeting PTEN by fusing an N-myristoylation (Myr) consensus sequence to its N-terminus. Also, a PTEN mutant lacking the N-terminal 16-aa PIP 2 -binding motif, ΔN16-PTEN, was included. The subcellular localization of these PTEN isoforms was verified by confocal microscopy (Fig. 3A) .
Next, the phosphorylation states of these PTEN isoforms were analyzed by phospho-specific antibodies directed against the p-Ser380 and pSer385 sites. These studies revealed that membrane-anchored PTEN has a ~60% reduction in phosphorylation of Ser380. A more modest 33% decrease in phosphorylation at Ser385 was observed, but this result was not statistical significant ( Fig. 3B and C ) . Furthermore, phosphorylation levels at these two sites were not significantly altered in the PTEN-ΔN16 mutant.
Phosphorylation State of PTEN C-tail affects its
Phosphatase Activity-Several studies have characterized the tumor suppressing activities of various C-tail phosphorylation site mutants (21, 33) . However, how individual phosphorylation sites contribute to the innate catalytic property of PTEN has not been extensively investigated. For this, PTEN C-tail mutants were fused with a histidine (His) tag at the N-terminus and expressed in Sf9 insect cells. These proteins were affinity purified through a Nickel column and monomeric PTEN was further isolated by gel filtration. This strategy was preferred over recombinant proteins produced in bacteria, since in our hands, PTEN generated by this method formed extensive aggregates. More importantly, bacterially produced PTEN harbored a higher intrinsic phosphatase activity making comparison between different PTEN mutants less amenable (unpublished observations).
Since PIP 2 has been shown to augment PTEN lipid phosphatase activity (16, 18, 19) , either PIP 3 alone or PIP 2 and PIP 3 in combination were used as substrates in our assays. As shown in Fig. 4A , the single site mutants S370A, S380A, T382A and T383A possessed a 2-3 fold decrease in their catalytic activity when compared with the wildtype protein. However, these mutants still responded to the stimulatory action of PIP 2 . On the contrary, the S385A, the double and triple site mutants all had a 2-3 fold increase in phosphatase activity. However, PIP 2 failed to further stimulate their catalytic activity.
For mutants with enhanced catalytic activity, their phosphorylation levels at Ser380, Thr382, and Thr383 were examined. Western blotting analysis using phospho-specific antibodies revealed a significant reduction in phosphorylation at the Ser380 and the Ser380/Thr382/Thr383 cluster in the S385A mutant and even greater for the S370A/S385A double mutant (Fig. 4C and D) . Consistently, a S380D/T382E/T383E/S385A mutant harbored a reduced enzymatic activity when comparing to the S385A mutant (Fig. 4B) . Thus, phosphorylation at the S380/T382/T383 cluster may be positively regulated by phosphorylation events at position Ser370 and Ser385.
PTEN C-tail Interacts with the C2 Domain-To gain mechanistic insights into the roles of PTEN C-tail in membrane binding and catalysis, we conducted the following two sets of experiments. First, we investigated if C-tail could mediate intramolecular interactions with PTEN domains implicated in membrane-binding. Next, the ability of the C-tail in inhibiting PTEN enzymatic activity was analyzed.
The flexible nature of the C-tail region could potentially favor dynamic intra-molecular interactions to regulate PTEN biochemical properties. To test this possibility, functional domains of PTEN were examined for their ability to interact with a FLAG-tagged C-terminal tail region (FLAG-C-tail) encompassing aa333-403 (Fig. 5A ). For this, co-immunoprecipitation assays were carried out in 293T cells transiently overexpressing various PTEN fragments. The FLAG-C-tail only weakly immunoprecipitated the full length PTEN, WT; and an N-terminal truncated PTEN, Δ N16. (Fig. 5B ) . More significantly, FLAG-C-tail efficiently coimmunoprecipitated with the C-terminal half (CTD) of PTEN. Similar result was not observed when immunoprecipitation was carried out using an isotype immunoglobulin (Ig) (Fig. 5C) . Also, the CTD was not present in the immunoprecipitates when the FLAG-C-tail was not transfected (Fig.  5C ). This interaction was also verified by reverse immunoprecipitation using an AU5 epitope-tagged CTD, CTD-AU5 (Fig. 5D ) . Furthermore, the interaction observed was unlikely due to the formation of tail-tail homodimers since the C-tail tagged with a different epitope (AU5) failed to display co-immunoprecipitation (Fig. 5E ). We have further confirmed the direct binding between bacterially produced C-tail and in vitro-translated CTD (Fig. S1) .
Raftopoulu et. al. have previously reported the interaction between the PTPase domain and the CTD, and that this interaction required the presence of the C-tail region. We have confirmed this interdomain interaction using similar PTEN constructs ( Fig. 6A and B) . However, we failed to detect any detectable co-immunoprecipitation between the PTPase domain and the C-tail alone (Fig. 6C) . From these data, we conclude that the 70-aa C-tail region of PTEN interacts with the C2 domain. These and previous results raise the possibility that PTEN C-tail may interface the catalytic domain through interacting with the C2 domain.
The C-tail Interacts Extensively with the CBRIII
Motif of the C2 domain-To map the residues in the C2 domain involved in the interaction with the C-tail, a panel of CTD truncation mutants were constructed (Fig. 7A) . The relative ability of these mutants to immunoprecipitate the FLAG-C-tail was then analyzed (Fig.7B) . We observed that the interaction was nearly abrogated when residues 255-280 were removed. Interestingly, this region was corresponding to the CBRIII loop of the C2 domain implicated in membrane association (12, 13) . However, substitutions of all the basic residues at Lys260, Lys263, Lys266, Lys267, and Lys269 to alanines (CBRIII mutant) did not significantly reduce binding to FLAG-C-tail (Fig.  S2) .
Furthermore, substituting additional positively charged, solvent exposed residues at the Lys327, Lys330, Lys332, and Arg335 (Cα 2 mutant) also did not attenuate the interaction between CTD and FLAG-C-tail (Fig. S2) . Thus, these results indicate that the interaction between the C-tail and the C2 domain most likely involved extensive interface on multiple sites. Alternatively, the interactions observed are non-electrostatic in nature.
The C-tail Domain Inhibits the Catalytic Activity of PTEN in a Phosphorylation Dependent
Manner-Based on our data, the interaction between C-tail and the C2 domain could potentially be extended into the PTPase domain. In addition, mutating phosphorylation sites within PTEN C-tail led to a greater intrinsic phosphatase activity. Indeed, numerous proteins involving in catalysis harbored auto-inhibitory domains that could regulate intrinsic enzymatic activities. Furthermore, PTEN displayed a high affinity for acidic substrates and may mediate the autodephosphorylation of Ser383 in the tail region (33) . To investigate whether the C-tail could act as an autoinhibitory domain, two peptides were synthesized. The Cp-23 peptide encompassed the phosphorylation cluster between residues 368-390 of the C-tail (Fig. 8A ) . A corresponding phosphomimic peptide, Cp-23DE, was used with the serines at the positions 370, 380, and 385 changed to aspartic acid, and the threonines at the positions 382 and 383 changed to glutamic acid.
The relative ability of these peptides to inhibit the phosphatase activity of PTEN was tested using PIP 3 as a substrate. As shown in Fig. 8B , the Cp-23 peptide inhibited PTEN activity with an IC 50 of 944.7 ± 44.8 µM. More importantly, the Cp-23DE peptide exhibited a significantly greater inhibitory activity with an IC 50 of 323.3 ± 13.2 µM. In addition, a randomized Cp-23DE peptide (Cp23DEr) was tested to ensure specificity. As expected, the Cp-23DEr peptide displayed an IC 50 very similar to that of the Cp-23 peptide.
To investigate weather the C-tail peptide could inhibit PTEN catalytic activity in cultured cells, expression plasmids of GFP-fused Cp-23 and a phospho-mimic Cp-23/385E were transfected in 293T cells. Both fusion proteins were able to significantly decrease the membrane localization of PTEN when compared to the GFP control (Fig.  9A ). This observation was correlated with a 2.5-fold increase in p-AKT in cells transfected with the GFP-Cp-23/385E plasmid (Fig. 9B) . A similar stimulation of p-Akt, albeit weaker, was also observed in cells expressing GFP-Cp-23. The fact GFP-Cp-23 possessed inhibitory activities on PTEN could be explained by the fact that both S380 and S385 were phosphorylated (Fig. 9C) . Thus, these results demonstrated that the phosphorylation cluster within the C-tail region plays an inhibitory function on PTEN membrane targeting and catalytic activities.
DISCUSSION
By mass spectroscopy (MS), two groups have identified Ser370, and Ser385 as the major phosphorylation sites of PTEN when expressed in mammalian cells (30) . We have independently used MS to analyze a CKII phosphorylated peptide encompassing aa372-394 of PTEN. We found the peptide to be phosphorylated exclusively at Ser385 (unpublished observations). This result raises the possibility that additional kinase(s) could be involved in the phosphorylation of Ser380, Thr382, and Thr383.
The panel of PTEN mutants has provided insights into the role of individual phosphorylation sites to the intrinsic properties of PTEN. Among the mutants we have characterized, the S370A mutant does not significantly differ from the wildtype protein. It has been reported that the phosphorylation at Ser370 can prime the phosphorylation of Ser366 by GSK-3β (29) . However, mutating Ser366 did not result in any detectable changes in PTEN activities (data not shown). Thus, the biological relevance of Ser366 phosphorylation by GSK-3β is still unclear.
Mutating Ser380 to either alanine or glutamic acid enhances PTEN membrane-binding capacity, but anchoring PTEN to the membrane decreases its phosphorylation state. Intriguingly, PTEN phosphorylated at Ser380 constitutes only a minor pool of total PTEN in vitro (30) . To reconcile these contradictory findings, we make the following two speculations. First, Ser380 most likely plays a structural role in regulating PTEN membranebinding capacity. For instance, mutating Ser380 to either alanine or glutamic acid induces a conformational change in the tail region to unmask membrane-binding motifs. The second possibility is that PTEN with Ser380 phosphorylated constitutes only a small transient pool of PTEN that undergoes rapid turnover during membrane binding. Indeed, our data does not exclude the possibility that phosphorylation of Ser380 could promote PTEN membrane targeting. Once bound, p-Ser380 could be dephosphorylated as demonstrated by the myr-PTEN mutant. We are currently attempting to isolate a sufficient quantity of endogenous membrane-bound PTEN in order to determine the composition of the phosphorylated residues.
Our results with the Ser385 mutants highlight the importance of phosphorylation and dephosphorylation events at this site in regulating PTEN membrane binding and catalytic activities. We have shown that the S385A mutant promotes PTEN activities while S385E has the opposing effects. Thus, it is likely that dephosphorylation at Ser385 precedes membrane binding. Indeed, myr-PTEN has only a modest decrease in p-Ser385.
There have been suggestions that phosphorylation at Ser385 may prime the phosphorylation of Thr383 by CKII (24, 29, 35) . Indeed, by using a phospho-specific antibody directed against p-S380/p-T382/p-T383, we have detected a significant reduction in the level of phosphorylation at these three positions in both the S385A and S370A/S385A mutants. However, we are unable to discern whether the higher phosphatase activity and membrane localization observed with these two mutants is solely due to mutations in Ser385 and Ser370, or it is an indirect effect of the lack of phosphorylation at Ser380/Thr382/Thr383. However, the lower p h o s p h a t a s e a c t i v i t y o f t h e S380D/T382E/T383E/S385A mutant when comparing with S385A tends to argue for the importance of dephosphorylation at Ser380/Thr382/Thr383. It is important to point out that the anti-3P antibody only provides an overall phosphorylation state of PTEN. It does not specific which residues that are phosphorylated. Thus, it is pertinent to analyze in the future the exact residues that are being dephosphorylated in the S385A mutant.
Currently, there is no evidence to suggest that phosphorylation events at Ser370 or Ser385 are regulated. Rather, these sites are most likely to be constitutively phosphorylated, and may play a role in priming additional phosphorylation events. On the contrary, the levels of phosphorylation at Ser380, Thr382 and Thr383 have been shown to be up-regulated in hypothalamic cells treated with leptin (32), ischemic brain tissues (36) , acute myelogenous leukemia (37) , and human fibromyomatous uteri (38) . In these cases, phosphorylation presumably inhibits PTEN lipid phosphatase activity.
Our data provide evidence that PTEN Cterminus possesses auto-inhibitory functions. It is mediated by the direct interference of both the C2 and phosphatase domains. The idea that the C-tail can block membrane binding through masking actions on positively charged residues has been inferred (14) . For instance, the C-tail is believed to form electrostatic interaction with cationic residues at positions Arg161, Lys163, and Lys164 in the Nterminal phosphatase domain region. To our knowledge, the present study is the first demonstration of the direct interaction of the tail region with the C2 domain of PTEN.
The C2 domain of PTEN lacks most of the residues required for binding calcium (12) . However, it possesses the CBRIII motif that is composed of four cationic residues at Lys263, Lys266, Lys267, and Lys269, implicated in electrostatic interactions with the plasma membrane. Although the ability of the C-tail to bind the C2 domain was drastically reduced when the CBRIII motif was deleted, substitutions of all four positively-charged residues did not affect the interaction. Therefore, it is unlikely that the phosphorylation cluster within the C-tail could mediate direct interaction with the C2 domain. Rather, cryptic binding motifs within the PTEN Ctail may interact with the CBRIII region through non-electrostatic means.
Using a phospho-mimic peptide from the Ctail, we have shown that it can inhibit PTEN catalytic activity in a dose-dependent manner, suggesting that the C-tail acts as an autoinhibitory domain. A similar inhibitory domain with comparable IC 50 has been described for the calcineurin phosphatase (39) . This data points to the possibility that the phosphorylation sites between Ser380 to Ser385 could act as a pseudosubstrate, competing with PIP 3 for the catalytic pocket. Since acidic peptides are poor substrates for PTEN, the C-tail may serve as an ideal pseudosubstrate by forming a non-productive complex with the catalytic pocket. However, we cannot completely exclude the possibility that the phosphomimic peptide mediates its suppressive effects through binding to the C2 domain.
It is paradoxical that while the phosphorylation cluster can suppress PTEN catalytic activity, the C-tail fails to interact with the PTPase domain (Fig. 6) . We speculate that in order for the phosphorylation cluster to interact efficiently with the catalytic pocket, the C-tail needs to provide optimal positioning effects through interacting with the C2 domain. The exact nature these interactions will require additional structural data derive from biophysical methods.
Based on our data and previously published findings, it is possible to delineate a tentative model in which the C-tail regulates PTEN membrane targeting and catalytic activity. We favor a model in which PTEN C-tail exerts its inhibitory functions through a bipartite regulatory mechanism. First, the C-tail forms an extensive interaction with the CBRIII region of the C2 domain through non-electrostatic means. This in turn orientates the phosphorylation cluster between aa380-385 to mediate direct interaction with the catalytic pocket and inhibits PTEN enzymatic activity. As a result, PTEN attains a closed conformation and localizes predominantly in the cytosol. Conversely, the dephosphorylation of Ser385 triggers a cascade of events that will unmask the catalytic pocket and the C2 domain. PTEN attaining this activation state has a high affinity for plasma membrane and can dephosphorylate PIP 3 with great efficiency.
into membrane (MB) and cytosolic (CYT) fractions. B, Cells were solubilized in 0.01% saponin buffer and the insoluble (MB) and soluble (CYT) fractions were separated by centrifugation. PTEN expression was determined by Western blotting analysis. LDH and R-Ras were used as cytosolic and membrane markers, respectively. C, Cell extracts were fractionated into cytosolic (CYT) and nuclear (NU) fractions with the NE-PER kit. SP1 and LDH were used as nuclear and cytoplasmic markers, respectively. D, Cell extracts were fractionated by a 5-30% sucrose gradient. Individual fractions were analyzed for the expression of PTEN and the marker for lipid rafts, caveolin. by guest on November 7, 2017 
